The use of a single daily theophylline dose and metered-dose albuterol in asthma treatment.
Sustained-release, 24-hour theophylline preparations have been formulated and may provide for convenient once-a-day dosing, although the use of such products in clinical asthma has yet to be fully established. This study compared single daily versus twice daily dosing with a 24-hour theophylline, Uniphyl, in asthma and further evaluated for the additional effect of metered-dose albuterol on each theophylline regimen. Twenty-eight patients with asthma were enrolled in this randomized crossover trial. Before enrollment, all demonstrated at least a 15% improvement in FEV1 after a beta-adrenergic aerosol and had serum theophylline levels ranging from 5 to 20 micrograms/ml with a predetermined 800 mg daily dose of Uniphyl. The patients were then randomly entered into four treatment regimens for one week each: Uniphyl, 800 mg four times a day (qd); metered-dose albuterol, active, 180 micrograms four times a day (qid); Uniphyl, 400 mg twice daily; metered-dose albuterol, active, 180 micrograms qid; Uniphyl, 800 mg qd; placebo, two puffs qid; and Uniphyl, 400 mg twice daily; placebo, two puffs qid. On the morning of the seventh day of each treatment regimen, pulmonary functions and a trough serum theophylline level were measured. The patient then received the same medication that he had taken for the preceding week. Spirometry was measured hourly, and a serum theophylline level was measured 6 hours later. The daily symptom scores, peak flow values, and pulmonary functions on the test day were similar with either single or twice daily Uniphyl dosing. Routine administration of albuterol by metered dose did not enhance asthma control in an unequivocal fashion.(ABSTRACT TRUNCATED AT 250 WORDS)